Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$301 Mln
Revenue (TTM)
$100 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
5.3
P/B Ratio
7.8
Industry P/E
24.51
EV/EBITDA
31.7
Div. Yield
0 %
Debt to Equity
1.8
Book Value
$--
EPS
$-0.4
Face value
--
Shares outstanding
54,384,200
CFO
$-153.00 Mln
EBITDA
$-117.19 Mln
Net Profit
$-196.51 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alimera Sciences (ALIM)
| 28.2 | -0.7 | 70.5 | 66.9 | 4.5 | -2.1 | -22.9 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Alimera Sciences (ALIM)
| 59.4 | -47.2 | 21.6 | -44.3 | -29.6 | -45.8 | 23.1 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone... acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia. Read more
CEO & Director
Mr. Richard S. Eiswirth Jr.
CEO & Director
Mr. Richard S. Eiswirth Jr.
Headquarters
Alpharetta, GA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Alimera Sciences Inc (ALIM) is $5.54 (NASDAQ) as of 18-Sep-2024 09:30 EDT. Alimera Sciences Inc (ALIM) has given a return of 4.46% in the last 3 years.
The P/E ratio of Alimera Sciences Inc (ALIM) is 5.28 times as on 18-Sep-2024, a 78 discount to its peers’ median range of 24.51 times.
The P/B ratio of Alimera Sciences Inc (ALIM) is 7.77 times as on 18-Sep-2024, a 37 premium to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-5.58
|
2.43
|
|
2022
|
-1.05
|
-0.91
|
|
2021
|
-8.21
|
-13.79
|
|
2020
|
-3.95
|
-2.64
|
|
2019
|
-3.63
|
-8.53
|
The 52-week high and low of Alimera Sciences Inc (ALIM) are Rs -- and Rs -- as of 04-Apr-2026.
Alimera Sciences Inc (ALIM) has a market capitalisation of $ 301 Mln as on 18-Sep-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Alimera Sciences Inc (ALIM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.